All In Biotech

Drug Trial Radar · NCT07293065

A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell)

A Multicenter, Double-Blind, Placebo-Controlled Phase III Clinical Trial to Evaluate the Long-Term Protective Efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) in Adults Aged 40 Years and Above

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 12,000 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

12,000

Planned (sponsor's estimate)

Start

Dec 15, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Sponsor type
Industry
First posted
Dec 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the sutdy is to evaluate the protective efficacy of Recombinant Herpes Zoster Vaccine (CHO Cell) (hereinafter referred to as "the investigational vaccine") in preventing herpes zoster at 13-36 months after complete immunization with the 0- and 2-month immunization schedule in individuals aged 40 years and older.

Conditions

  • Herpes Zoster

Interventions

  • Recombinant Zoster Vaccine (CHO Cell)Biological

    0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with MA105. Intramuscular injection

  • NaCl solution PlaceboBiological

    0.5 mL per dose, containing 4.5 mg sodium chloride. Intramuscular injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The person-year incidence of confirmed herpes zoster cases among individuals aged 40 years and older, 13 to 36 months after completing the full vaccination course with the investigational vaccine according to the 0- and 2-month immunization schedule.Time frame: At 13~36 months after the last vaccination

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Hebei Provincial Center for Disease Control and Prevention

    Shijiazhuang, Hebei, China

  • Henan Center for Diseases Control and Prevention

    Zhengzhou, Henan, China

  • Hubei Provincial Center for Disease Control and Prevention

    Wuhan, Hubei, China

  • Yunnan Center For Disease Control and Prevention

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.